Advances in optical imaging methods, personal computer power and cell/molecular biology methodology have merged to form the field of ‘Cellomics’1 also referred to as High Content Cellular Imaging (HCCI). HCCI is a powerful and flexible cell-based assay platform that has the potential to shorten cycle times by broadly impacting the Drug Discovery process from Target Validation/Lead Generation through in vitro support of Clinical Candidates. This article provides an overview of HCCI, contrasts it with conventional cell based assay modalities, and provides general examples of the technology’s effects on the Drug Discovery process at Eli Lilly and Company.
Sorry, this page is available to members only.
If you have not registered with us yet, why not
register today for FREE and receive exclusive online access. Interested in receiving European Pharmaceutical Review in print? Subscribe today and guarantee the next six issues delivered direct to your desk, plus gain exclusive access online.
